{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:19:00Z","timestamp":1780568340060,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jcf.2025.10.004","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:06:09Z","timestamp":1760544369000},"page":"1027-1030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic impact of elexacaftor\/tezacaftor\/ivacaftor on healthcare expenditure in Canada"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-3531","authenticated-orcid":false,"given":"Stephen E.","family":"Congly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjani","family":"Somayaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Parkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-6211","authenticated-orcid":false,"given":"Christina S.","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2025.10.004_bib0001","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.1038\/s41598-023-35942-7","article-title":"Factors associated with frequent high-cost individuals with cystic fibrosis and their healthcare utilization and cost patterns","volume":"13","author":"Desai","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jcf.2025.10.004_bib0002","first-page":"145","article-title":"Hospital costs of Canadian cystic fibrosis patients","volume":"6","author":"Skolnik","year":"2022","journal-title":"Crit Care Sleep Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.004_bib0003","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcf.2024.09.023","article-title":"Regulatory delays in approval of CFTR modulating agents in Canada","volume":"24","author":"Thornton","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.004_bib0004","unstructured":"Canadian Institute for Health Information. Impact of trikafta on individuals living with cystic fibrosis [Internet]. 2024. Available from: https:\/\/www.cihi.ca\/en\/impact-of-trikafta-on-individuals-living-with-cystic-fibrosis."},{"key":"10.1016\/j.jcf.2025.10.004_bib0005","unstructured":"Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta): CADTH reimbursement recommendation: indication: for the treatment of cystic fibrosis in patients aged 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene [Internet]. ottawa (ON): canadian agency for drugs and technologies in health; 2023 [cited 2025 may 31]. (CADTH Reimbursement Reviews and Recommendations). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599836\/."},{"key":"10.1016\/j.jcf.2025.10.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2024.100171","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States","volume":"7","author":"Pena","year":"2025","journal-title":"JHLT Open"},{"key":"10.1016\/j.jcf.2025.10.004_bib0007","unstructured":"Canadian Institute for Health Information. CIHI\u2019s strategic plan 2022-2027 [Internet]. 2022. Available from: https:\/\/www.cihi.ca\/sites\/default\/files\/document\/cihi-strategic-plan-2022-2027-en.pdf."},{"key":"10.1016\/j.jcf.2025.10.004_bib0008","series-title":"Impact of trikafta on individuals living with cystic fibrosis methodology notes [Internet]","year":"2024"},{"key":"10.1016\/j.jcf.2025.10.004_bib0009","unstructured":"Alberta Health and Wellness. Alberta health care insurance plan : schedule of medical benefits as of 14 march 2025 [Internet]. 2025. Available from: https:\/\/open.alberta.ca\/publications\/somb-2025-03-14."},{"key":"10.1016\/j.jcf.2025.10.004_bib0010","unstructured":"Alberta Blue Cross. Interactive drug benefit list [Internet]. 2025. Available from: https:\/\/idbl.ab.bluecross.ca\/idbl\/load.do."},{"issue":"1","key":"10.1016\/j.jcf.2025.10.004_bib0011","doi-asserted-by":"crossref","first-page":"E182","DOI":"10.9778\/cmajo.20180108","article-title":"Variable access to antiviral treatment of chronic hepatitis B in Canada: a descriptive study","volume":"7","author":"Congly","year":"2019","journal-title":"CMAJ Open"},{"issue":"4","key":"10.1016\/j.jcf.2025.10.004_bib0012","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1016\/j.jcf.2025.10.004_bib0013","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s41030-023-00241-z","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on healthcare resource utilization and associated costs among people with cystic fibrosis in the US: a retrospective claims analysis","volume":"9","author":"Schechter","year":"2023","journal-title":"Pulm Ther"},{"issue":"7","key":"10.1016\/j.jcf.2025.10.004_bib0014","first-page":"721","article-title":"Analyzing the use and impact of elexacaftor\/tezacaftor\/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population","volume":"28","author":"Smith","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.jcf.2025.10.004_bib0015","first-page":"599","article-title":"Real-world outcomes and direct care cost before and after elexacaftor\/tezacaftor\/ivacaftor initiation in commercially insured members with cystic fibrosis","volume":"29","author":"Marshall","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jcf.2025.10.004_bib0016","series-title":"Ivacaftor\u2013tezacaftor\u2013elexacaftor, tezacaftor\u2013ivacaftor and lumacaftor\u2013ivacaftor for treating cystic fibrosis (TA988) [Internet]","year":"2024"},{"key":"10.1016\/j.jcf.2025.10.004_bib0017","series-title":"Effectiveness and Value; Final Evidence Report and Meeting Summary [Internet]","article-title":"Modulator treatments for cystic fibrosis","author":"Tice","year":"2020"},{"key":"10.1016\/j.jcf.2025.10.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/20503121231225874","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with Phe508del mutation: evidence from randomized controlled trials","volume":"12","author":"He","year":"2024","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.jcf.2025.10.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/20406223241264477","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: a mixed methods exploratory study","volume":"15","author":"Basile","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2024-002309","article-title":"Socioeconomic burden of cystic fibrosis in Canada","volume":"11","author":"Laflamme","year":"2024","journal-title":"BMJ Open Respir Res"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:35:32Z","timestamp":1779953732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325024889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1569199325024889"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic impact of elexacaftor\/tezacaftor\/ivacaftor on healthcare expenditure in Canada","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}